Importantly, the rate of weight regain after discontinuation of medication was faster than after the end of intensive behavioral weightmanagement programs, even when the initial weight loss was similar
Arun Sanyal, M.D., chief of the Division of Gastroenterology, Hepatology and Nutrition and director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health MASH affects around 15 million Americans, and currently there is only one FDA-approved treatment available, increasing the urgency for effective therapeutic options
This prompts a local inflammatory response
Untargeted metabolomics, although still not implemented in routine clinical practice, has been shown to be a promising approach in screening of underlying biochemical abnormalities, discovering new specific biomarkers and directing treatment ( An interesting study was done in Greece where a large cohort of children with confirmed ASD were screened for the presence of IEM (Spilioti et al., 2013)
But some of the medication's other effects digestive discomfort , headaches , and low blood sugar could make it harder to sleep
